antithyroid agent
Jump to navigation
Jump to search
Indications
- treatment of hyperthyroidism, thyrotoxicosis[1]
Monitor
- thyroid function every 3 months
- prothrombin time every 3 months
Adverse effects
- use during the first trimester of pregnancy associated with increased risk for congenital malformations[2]
Mechanism of action
- agents that inhibit the action, release or production of thyroid hormone
More general terms
More specific terms
References
- ↑ Jump up to: 1.0 1.1 Deprecated Reference
- ↑ Jump up to: 2.0 2.1 Seo GH, Kim TH, Chung JH Antithyroid Drugs and Congenital Malformations: A Nationwide Korean Cohort Study. Ann Intern Med. 2018. Jan 23 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29357398 <Internet> http://annals.org/aim/article-abstract/2670322/antithyroid-drugs-congenital-malformations-nationwide-korean-cohort-study
- ↑ Vicente N, Cardoso L, Barros L, Carrilho F. Antithyroid Drug-Induced Agranulocytosis: State of the Art on Diagnosis and Management. Drugs R D. 2017 Mar;17(1):91-96. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28105610 Free PMC Article